2202 results about "Staphylococcus aureus bacteria" patented technology

The invention discloses bacillus velezensis as well as fermentation product filtrate and a biological product thereof, and belongs to the technical field of microorganisms, a bacillus velezensis BTN-HB-F4 strain is separated and purified from prinsepia utilis royle in Harba snow mountain in Yunnan province, the fermentation product filtrate of the bacillus velezensis has excellent HAS inhibition capacity and remarkable DPPH and ABTS free radical scavenging capacity, and the biological product of the bacillus velezensis has the advantages that the biological product can be used for preparing biological products of the prinsepia utilis royle; a good anti-oxidation effect can be realized; secondly, under various concentrations, fermentation product filtrate can remarkably reduce the proportion of SA-beta-Gal positive cells, gene expression of matrix metalloproteinase 3 can be remarkably inhibited, and a good anti-aging effect is achieved; in addition, fermentation product filtrate can remarkably inhibit generation of zebra fish melanin and has a good whitening effect; the secretion amount of cell inflammatory factors IL-6 and TNF-alpha can be remarkably inhibited, and a good relieving effect is achieved; finally, the fermentation product filtrate can effectively inhibit the growth of pathogenic bacteria staphylococcus aureus, and has the potential of regulating the skin micro-ecology.

The invention discloses a polyrotaxane covalent organic framework material capable of regulating interlayer spacing through cyclodextrin and application of the polyrotaxane covalent organic framework material, and belongs to the technical field of biological medicine. The polyrotaalkylated covalent organic framework material is obtained by taking a cyclodextrin aromatic multi-amino inclusion compound and a (multi-aldehyde bipyridine) ruthenium (II) complex as structural units and carrying out copolymerization; the cyclodextrin aromatic polyamine inclusion compound is a beta-cyclodextrin p-phenylenediamine inclusion compound with a hydroxyl group or without a hydroxyl group; the (multi-aldehyde dipyridyl) ruthenium (II) complex is tris (4, 4 '-diformaldehyde-2, 2'-dipyridyl) ruthenium (II). The interlayer spacing of the polyrotaxane covalent organic framework material is greatly increased by utilizing a cavity of gamma-cyclodextrin, and meanwhile, the material has excellent photo-thermal and photodynamic activity, is positively charged, and can better adsorb negatively charged bacteria; and the hydrogel is good in biocompatibility and free of toxic and side effects, and has an excellent treatment effect on wounds infected with staphylococcus aureus.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof in bacteriostasis. Specifically, the preservation number of the plant lactobacillus LP06 is CGMCC (China General Microbiological Culture Collection Center) No. 28412. The plant lactobacillus LP06 provided by the invention can be used for inhibiting the growth of debaryomyces hansenii, candida tropicalis and penicillium rochei, and also has an inhibiting effect on super bacteria acinetobacter baumannii, pseudomonas aeruginosa, klebsiella, escherichia coli, staphylococcus aureus and listeria monocytogenes. The plant lactobacillus LP06 provided by the invention has broad-spectrum bacteriostatic ability, and bacteriostatic powder prepared from the bacterium can be used as a biological preservative for corrosion prevention of dairy products such as yoghourt, cheese and the like and other foods.

The invention provides a Lactobacillus paracasei, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The lactobacillus paracasei ID001 provided by the invention has an inhibition effect on enteropathogenic bacteria such as salmonella, escherichia coli, staphylococcus aureus and the like. The probiotic preparation is obtained through fermentation and the dendrobium officinale extract, and the probiotic preparation has the immunoregulation effect through performance verification and screening.

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP1111NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention provides a nucleic acid composition for respiratory tract pathogen detection and application thereof, and relates to the technical field of biology. The invention provides a nucleic acid detection composition which has high specificity and can be used for detecting various respiratory pathogens. The composition can be used for detecting influenza B virus, influenza A virus H1N1, influenza A virus H3N2, novel coronavirus N gene, novel coronavirus O gene, respiratory syncytial virus, I-type parainfluenza virus, II-type parainfluenza virus, III-type parainfluenza virus, IV-type parainfluenza virus, rhinovirus, adenovirus, haemophilus influenzae, and the like. The kit has 15 pathogens including streptococcus pneumoniae and staphylococcus aureus, the lower detection limit can be as low as 20 copies / reaction, and the kit plays an important role in rapid detection of respiratory tract pathogens.

The invention provides a test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of the test strip, and belongs to the technical field of biochemical detection. The test strip comprises a bottom plate, a sample pad, a combination pad, a detection pad and a water absorption pad, the two ends of the detection pad are in lap joint with the combination pad and the water absorption pad respectively, the detection pad is located on the lower portion, the sample pad is in lap joint with the combination pad, and the combination pad is located on the lower portion; a detection line and a quality control line are arranged on the detection pad, the detection line is arranged on one side close to the combination pad, and the quality control line is arranged on one side close to the water absorption pad; the detection pad is coated with a MoS2 nanosheet, the combination pad is coated with a penicillin binding protein 2a polyclonal antibody labeled by horse radish peroxidase, and the detection line is coated with a penicillin binding protein 2a monoclonal antibody; the quality control line is coated with goat anti-rabbit IgG (immunoglobulin G). The kit is high in sensitivity and wide in linear range, has good specificity, repeatability and stability, and can effectively detect MRSA in a clinical sample.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1, the number of amino acids is small, the synthesis cost is low, the antibacterial peptide has high antibacterial activity on gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration of the antibacterial peptide on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is 4.68-37.5 mu g / mL, and the antibacterial peptide has the advantages of broad-spectrum antibacterial property, good stability and good application prospect. No obvious cytotoxicity and hemolysis effect exist; moreover, end-to-end amido bond cyclization is carried out, so that the antibacterial activity is further enhanced, the antibacterial effect on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is enhanced by 2-4 times, and the minimum inhibitory concentration is reduced to 2.34-9.38 mu g / mL; after the end-to-end amido bonds are cyclized, the plasma stability and safety of the antibacterial peptide are further improved, and the cytotoxicity and hemolysis are reduced.

The invention discloses staphylococcus NHY-25 capable of producing enzyme and aroma, which is preserved in Guangdong Microbial Culture Collection Center on May 26, 2025, and the preservation number is GDMMC NO: 66396. When the strain is applied to yeast strengthening, the enzyme activity in high-temperature yeast can be improved, for example, the activity of protease, saccharifying power, fermenting power and liquefying power of yeast can be improved. Through detection of volatile compounds in the strengthened Daqu and the unstrengthened Daqu, it is found that the strain enables the variety and content of the volatile compounds in the strengthened Daqu to be improved. The strain enables the sauce flavor of high-temperature yeast to be more prominent, can be applied to yeast strengthening, and provides a new thought for improving the quality of yeast.

The invention discloses a hydrogel dressing with a double-slow-release effect as well as a preparation method and application of the hydrogel dressing. The preparation method of the hydrogel dressing comprises the following steps: firstly, preparing methyl acrylate modified hyaluronic acid capable of being photo-crosslinked, then preparing carboxymethyl chitosan nanoparticles loaded with chlorogenic acid, and finally, mixing the methyl acrylate modified hyaluronic acid and the carboxymethyl chitosan nanoparticles loaded with chlorogenic acid to obtain the hydrogel dressing. The hydrogel dressing embedded with the nanoparticles is obtained in a photo-crosslinking mode. The hydrogel dressing provided by the invention not only has good biocompatibility and mechanical properties, but also plays an anti-oxidation role by removing free radicals in a body, and can effectively kill bacteria such as escherichia coli and staphylococcus aureus to play an antibacterial role. The hydrogel dressing can also reduce excessive inflammatory response in the wound healing process by influencing macrophage polarization, promote chronic wound healing and relieve pain of patients.

The invention relates to the technical field of hydrogel, in particular to a preparation method and application of EGCG-mediated hydrogel, a lysozyme solution is heated under the acidic condition to form lysozyme amyloid fibrils LAFs, EGCG is dissolved in a buffer solution and mixed with the LAFs solution obtained in the step 1 in proportion to form an LAFs-EGCG compound, and the EGCG-mediated hydrogel is prepared. The chitosan CS is dissolved in an acetic acid buffer solution, glutaraldehyde is added to serve as a cross-linking agent, the mixture is mixed with the LAFs-EGCG compound obtained in the step 2 and stirred, the composite hydrogel is formed, the concentration of EGCG is 0.2-1.0 wt%, the concentration of LAFs is 5 wt%, the concentration of chitosan is 2 wt%, the pH value of the lysozyme solution in the step 1 is 2.0, the heating temperature is 77 DEG C, the heating time is 10 hours, the concentration of EGCG in the step 2 is 0.4-0.8 wt%, and the pH value of the lysozyme solution in the step 2 is 1.5-2.5. In the step 3, the concentration of glutaraldehyde is 2%, the storage modulus G'of the hydrogel is 325-480 Pa, the hardness is 2176.71 g, and the bacteriostasis rate on staphylococcus aureus and salmonella exceeds 95%.

The invention discloses an antibacterial peptide based on D-type amino acid and application of the antibacterial peptide, and the antibacterial peptide is characterized in that the amino acid sequence is w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized through an Fmoc solid-phase chemical method, the synthesis difficulty is low, and the in-vivo antibacterial activity is good. The antibacterial peptide especially has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, is low in hemolytic toxicity, can reach half or more of cell survival rate under medium and low concentration, almost has no toxic effect on cells, and can be used for preparing the antibacterial peptide with a broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus. The stability is good, the operability is high, and the cost is low.

The invention relates to Penicillium decumbens C01 and application of the Penicillium decumbens C01, and belongs to the technical field of microorganisms. The penicillium decumbens C01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the penicillium decumbens C01 is GDMCC NO.66456. The strain is obtained by separating, purifying and screening soil samples collected from botanical gardens in South China of Guangzhou; tests show that the bacteriostatic active substance generated by fermentation of the strain has a good bacteriostatic effect on staphylococcus epidermidis, staphylococcus aureus, escherichia coli, propionibacterium acnes, candida albicans and pseudomonas aeruginosa, and the bacteriostatic active substance has the characteristic of high temperature resistance and excellent preservative effect; the antibacterial preservative can be used as an antibacterial preservative raw material, is applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The invention belongs to the technical field of antibiosis and wound healing promotion, and relates to double-response (near-infrared light and hydrogen peroxide double-response photo-thermal / carbon monoxide therapy) antibacterial hydrogel as well as preparation and application thereof. The invention relates to a double-response antibacterial hydrogel. The antibacterial hydrogel is prepared from the following components: drug-loaded nano particles and a hydrogel matrix. The drug-loaded nano particles are prepared by loading dimanganese decacarbonyl (MnCO) into cavities of hollow mesoporous copper sulphide nano particles (HMCuS NPs) and coating the surfaces of the particles with a polydopamine layer (PDA). According to the invention, CO / PTT synergistic treatment of bacterial infected wounds is realized, and the antibacterial effect is significantly improved. An in-vitro antibacterial experiment result shows that the antibacterial hydrogel shows extremely strong inhibition capability on escherichia coli and staphylococcus aureus, and the problem of drug resistance caused by a bacterial biofilm is effectively solved.

The invention discloses preparation and application of an anti-staphylococcus aureus IsdB antibody. The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 8; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 16. The invention also provides nucleic acid for coding the antibody, a vector containing the nucleic acid and a cell containing the vector. In addition, experiments prove that the antibody can inhibit systemic infection of MRSA and resist invasion of MRSA to pneumonia, and has a good clinical application prospect.

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention discloses a Brucella with antibacterial activity and application of the Brucella. The invention discloses Burkholderia sp.HNIV0701, and the preservation number of the Burkholderia sp.HNIV0701 is GDMCC No: 66007. The Burkholderia sp.HNIV0701 disclosed by the invention has a stable, efficient and broad-spectrum antibacterial property, has an inhibition effect on a plurality of plant pathogenic bacteria such as Botryosphaeria dothidea, Phytophthora nicotianae, Fusarium solani, Alternaria alternata, Thanatepora cucurbitae, Ralstonia solanacearum and the like, and also can be used for inhibiting Staphylococcus aureus and / or Listeria monocytogenes, so that the Burkholderia sp.HNIV0701 can be used for inhibiting a plurality of plant pathogenic bacteria such as the Botryosphaeria dothidea, the Phytophthora nicotianae, the Fusarium solanum, the Alternaria solanacearum and the like. The Brucella HNIV0701 can hydrolyze organic phosphorus and can be used for soil improvement. The Brucella HNIV0701 has nitrogen fixation capability and has the potential of promoting plant growth.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The invention relates to a norhalal-enoxacin conjugate as well as a preparation method and application thereof. The norhalal-enoxacin conjugate comprises a norhalal-enoxacin coupling compound, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester or a pharmaceutically acceptable solvate selected from the compound. Compared with enoxacin, kanamycin, streptomycin, lincomycin and azithromycin, the norharmann-enoxacin conjugate disclosed by the invention has a smaller MIC (Minimum Inhibitory Concentration) value, which shows that the norharmann-enoxacin conjugate has a better anti-staphylococcus aureus effect.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses an antibacterial peptide fragment intercepted from chitinase IDGF4 protein and application of the antibacterial peptide fragment in preparation of antibacterial drugs. According to the invention, short peptide fragments in chitinase IDGF4 protein are screened, three candidate peptides are obtained through chemical synthesis, the antibacterial performance of the candidate peptides is systematically evaluated, and the evaluation result shows that the peptide fragment with the amino acid sequence as shown in SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg / mL; the antibacterial effect of the compound is confirmed in inhibition zone experiments, enzyme-labeled turbidimetry and growth curve monitoring, and the compound shows stable and remarkable antibacterial activity and can be used as a novel antibacterial molecule; the invention provides a new candidate sequence for developing the antibacterial peptide with high efficiency and low drug resistance risk, and has application potential in the aspect of preparing clinical antibacterial drugs.

The invention provides a kit for rapidly detecting MRSA and drug-resistant gene nucleic acid POCT of the MRSA based on a phage lyase mutant. The kit comprises nucleic acid extraction and purification and triple PCR rapid amplification detection reagents. The staphylococcus aureus bacteriophage lyase mutant nucleic acid release liquid containing the amino acid sequence as shown in SEQ ID NO: 1 is adopted, wall breaking can be rapidly conducted on staphylococcus aureus, and nucleic acid is released. The effect of the nucleic acid release liquid acting for 5 minutes is equivalent to or even better than that of the lysozyme acting for 60 minutes; according to the present invention, with the combination of the MRSA and drug-resistant gene triple PCR rapid amplification detection reagent, the total detection time is only 35 min, the time is saved by 55 min or more than 55 min compared with the lysozyme method, and the MRSA and drug-resistant gene nucleic acid POCT rapid detection can be achieved;

The invention discloses a staphylococcus aureus biosensor based on a nucleic acid aptamer and a preparation method of the staphylococcus aureus biosensor. Three fluorine atoms (F) are introduced into the 5'end, the 3 'end and the middle position of an aptamer 2' F3-(5 '3'm DNA) sequence (SEQ ID NO: 1) for modification, so that the binding force of the aptamer and graphene is remarkably enhanced, the signal stability and the anti-interference capability of the biosensor are remarkably improved, non-specific fluorescence leakage can be effectively blocked, and reliable guarantee is provided for complex sample detection. According to the present invention, with the cooperation of the graphene oxide quenching substrate, the high-sensitivity detection of the staphylococcus aureus is achieved, the detection limit of the sensor within 5 min can achieve 5 cells / mL, the sensitivity is high, the specificity on the complex sample is more than 95.4%, and the sensor is suitable for the food safety rapid screening and the clinical diagnosis.

The invention belongs to the technical field of microorganisms, and discloses a Lactobacillus paracasei B20 for inhibiting melanin from a plateau area and application of the Lactobacillus paracasei B20, the Lactobacillus paracasei B20 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32434, and the preservation date is October 31, 2024. Metabolite of the lactobacillus paracasei B20 comprises phenylalanine, p-hydroxycinnamic acid and the like, has strong tyrosinase inhibition effect and anti-ultraviolet ability, and can significantly reduce generation of melanin in skin. In addition, the lactobacillus paracasei B20 also has relatively strong oxidation resistance, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body. In addition, the lactobacillus paracasei B20 has a relatively obvious growth inhibition effect on skin conditioned pathogens such as staphylococcus aureus and enterococcus faecalis.